Company Profile: AusCann Group Holdings Ltd (ASX: AC8) is engaged in manufacturing and offering clinically validated cannabinoid medicines and aims to assist Australian patients in every regard. It has operations that run through different phases like cultivation and production, manufacture and distribution of products. The group was earlier known as TW Holdings Limited, and has been into cannabis cultivation for quite some time. They started with medications for neuropathic and chronic pain and have been targeting the opportunity in Australia primarily ($9 billion).
Start discussion with value Investors for ASX Stock Market Investment and Opinion.
Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s
Those phrases have become increasingly common as marijuana legalization spreads.
Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.
Click here for your FREE Report